{"result": "(\"entity\"<|>CU<|>EVENT<|>CU refers to Colitis Ulcerosa, a type of inflammatory bowel disease that requires treatment to induce and maintain remission.)\n##\n(\"entity\"<|>EC<|>EVENT<|>EC refers to Enfermedad de Crohn, another type of inflammatory bowel disease that can lead to malnutrition and requires various treatments.)\n##\n(\"entity\"<|>PREDNISONA<|>ORGANIZATION<|>Prednisona is a corticosteroid used to suppress inflammation in patients with inflammatory bowel disease.)\n##\n(\"entity\"<|>BUDESONIDA<|>ORGANIZATION<|>Budesonida is a corticosteroid that helps in the treatment of inflammatory bowel disease by reducing inflammation.)\n##\n(\"entity\"<|>CIPROFLOXACINO<|>ORGANIZATION<|>Ciprofloxacino is an antibiotic used in severe cases of inflammatory bowel disease to improve prognosis.)\n##\n(\"entity\"<|>CLARITROMICINA<|>ORGANIZATION<|>Claritromicina is an antibiotic that may be used in the treatment of severe inflammatory bowel disease.)\n##\n(\"entity\"<|>METRONIDAZOL<|>ORGANIZATION<|>Metronidazol is an antibiotic used for treating severe forms of inflammatory bowel disease, especially in perianal conditions.)\n##\n(\"entity\"<|>INFLIXIMAB<|>ORGANIZATION<|>Infliximab is a biological therapy that targets tumor necrosis factor (TNF) and is used in the treatment of inflammatory bowel disease.)\n##\n(\"entity\"<|>ADALIMUMAB<|>ORGANIZATION<|>Adalimumab is a monoclonal antibody used to treat inflammatory bowel disease by inhibiting TNF.)\n##\n(\"entity\"<|>GOLIMUMAB<|>ORGANIZATION<|>Golimumab is a monoclonal antibody that targets TNF and is used in the treatment of inflammatory bowel disease.)\n##\n(\"entity\"<|>CERTOLIZUMAB<|>ORGANIZATION<|>Certolizumab is a biological agent used to treat inflammatory bowel disease by targeting TNF.)\n##\n(\"entity\"<|>VEDOLIZUMAB<|>ORGANIZATION<|>Vedolizumab is a monoclonal antibody used in the treatment of inflammatory bowel disease, specifically targeting gut-specific integrins.)\n##\n(\"relationship\"<|>PREDNISONA<|>CU<|>Prednisona is a key treatment for managing inflammation in patients with Colitis Ulcerosa<|>8)\n##\n(\"relationship\"<|>BUDESONIDA<|>CU<|>Budesonida is used to suppress inflammation in patients with Colitis Ulcerosa<|>8)\n##\n(\"relationship\"<|>CIPROFLOXACINO<|>EC<|>Ciprofloxacino is used in severe cases of Enfermedad de Crohn to improve prognosis<|>7)\n##\n(\"relationship\"<|>CLARITROMICINA<|>EC<|>Claritromicina is used in the treatment of severe forms of Enfermedad de Crohn<|>7)\n##\n(\"relationship\"<|>METRONIDAZOL<|>EC<|>Metronidazol is used for treating severe forms of Enfermedad de Crohn, especially in perianal conditions<|>7)\n##\n(\"relationship\"<|>INFLIXIMAB<|>CU<|>Infliximab is a biological therapy used to treat Colitis Ulcerosa by targeting TNF<|>9)\n##\n(\"relationship\"<|>ADALIMUMAB<|>CU<|>Adalimumab is used to treat Colitis Ulcerosa by inhibiting TNF<|>9)\n##\n(\"relationship\"<|>GOLIMUMAB<|>CU<|>Golimumab is a monoclonal antibody used in the treatment of Colitis Ulcerosa<|>9)\n##\n(\"relationship\"<|>CERTOLIZUMAB<|>CU<|>Certolizumab is used to treat Colitis Ulcerosa by targeting TNF<|>9)\n##\n(\"relationship\"<|>VEDOLIZUMAB<|>CU<|>Vedolizumab is a monoclonal antibody used in the treatment of Colitis Ulcerosa, specifically targeting gut-specific integrins<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ina y aminosalicilatos (mesalamina, sulfasalazina, olsalazina y balsalacida)\n\nConstituyen la primera línea de tratamiento en la CU,\ntanto en la inducción como en el mantenimiento de la\nremisión16. Se pueden aplicar en forma de enemas o\nsupositorios para formas distales. Poseen acción antiin-\nflamatoria disminuyendo los radicales libres, el factor\nkappa-b-NFKB y la interleucina-1 (IL-1), inhibiendo los\nneutrófilos y estimulando la síntesis de prostranglandi-\nnas antiinflamatorias17.\n\n#### 2.4.2. Corticoides (prednisona, budesonida)\n\nLos corticoides han constituido un pilar clave en el tra-\ntamiento de los pacientes con EII. Habitualmente produ-\ncen una supresión importante de la inflamación y un\nrápido alivio de los síntomas y están indicados en los\nbrotes agudos de la enfermedad. Se utilizan para\nlos brotes, según la gravedad (orales en brotes leves-mo-\nderado o vía IV en los severos), existiendo preparaciones\ntópicas que disminuyen los efectos secundarios. Una vez\nconseguida la remisión, su empleo no garantiza evitar\nlas recaídas o un mejor pronóstico, por lo que no deben\nusarse como tratamiento de mantenimiento.\n\n#### 2.4.3. Antibióticos (ciprofloxacino, claritromicina, metronidazol)\n\nSe usan en formas severas (para mejorar el pronóstico\nen caso de perforación), o en caso de afectación perianal.\n\n#### 2.4.4. Inmunomoduladores (6-mercaptopurina, azatioprina, metotrexato, ciclosporina, tacrolimus, factor estimulador de granulocitos e infliximab y otros anti-TNF y anti-IFN gamma)\n\nEstán indicados como tratamiento de mantenimiento,\npero suelen tener inicios de acción relativamente lentos.\nPor ello, no están indicados en la fase aguda de la enfer-\nmedad y se utilizan para reducir o eliminar la corticode-\npendencia, mantenimiento de la remisión en EC y CU\ncuando fracasan los aminosalicilatos, en el tratamiento\nprimario de las fístulas y en el tratamiento alternativo\npara las recidivas por EC después de la corticoterapia.\n\n#### 2.4.5. Cirugía\n\nEn la CU la colectomía total es curativa. En la EC la\ncirugía debe circunscribirse a la resolución de esteno-\nsis, siendo lo más conservador posible18.\n---\n484      BLOQUE: NUTRICIÓN EN PATOLOGÍA DEL TUBO DIGESTIVO\n\n### 2.4.6. Terapias biológicas\n\nAnticuerpos monoclonales contra determinadas moléculas que juegan un papel importante en el proceso inflamatorio. Agentes antifactor de necrosis tumoral (anti-TNF) infliximab, adalimumab, golimumab,certolizumab y vedolizumab. Estos fármacos han venido a revolucionar el tratamiento de la EII y han supuesto un avance muy importante en los últimos años19 (ICAM-1, factor nuclear kappa-B, interleucina-10 (IL-10), interleucina-11 (IL-11), anticuerpos antileucocitarios, talidomida, monofetil micofenolato, hormona del crecimiento, tratamiento antituberculoso, leflunomida).\n\n### 2.4.7. Otros\n\nEn pacientes sometidos a gran estrés que tienen dificultades para su control pueden usarse ansiolíticos e incluso antidepresivos. Los antidiarreicos como loperamida pueden usarse para aliviar los síntomas cuando no hay complicaciones.\n\n## 3. Objetivos nutricionales\n\n### 3.1. Manifestaciones nutricionales\n\nSe relaciona una importante pérdida de peso y malnutrición de causa multifactorial (tabla 1). De modo general, la severidad de la malnutrición depende de la duración, actividad y extensión de la enfermedad. Es evidente que por su afectación a nivel del tubo digestivo la EII, tanto la CU como la EC, puede inducir desnutrición energético-proteica (DEP) así como déficit de micronutrientes con repercusión clínica. En la EC la desnutrición es lenta con grandes deficiencias crónicas que se agudizan en hospitalizaciones y en brotes severos. Sin embargo, en la CU se suele preservar el estado nutricional surgiendo grandes déficits en los momentos de actividad de la enfermedad.\n\nEn la EII existe DEP y déficit de micronutrientes en una proporción variable de pacientes, dependiendo del método y criterio para determinarla, dado el distinto curso clínico de la CU y la EC (generalmente brotes agudos en la\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}